BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 7516376)

  • 1. [Terazosine in the treatment of benign prostatic hypertrophy].
    Caine M
    J Urol (Paris); 1993; 99(6):311-3. PubMed ID: 7516376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical efficacy and safety of terazosine (setegis) in patients with benign prostatic hyperplasia with concomitant cardiovascular diseases].
    Trapeznikova MF; Gurevich MA; Pozdniakov KV; Tazina SIa; Bychkova NV
    Urologiia; 2005; (2):50-3. PubMed ID: 15989029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A multicenter, fixed-flexible dose study of terazosin hydrochloride in the treatment of symptomatic benign prostatic hypertrophy].
    Park YC; Nishioka T; Arai Y; Tomoyoshi T; Kurita T; Hayashida H; Nagai N; Inoue H; Kataoka K; Kitagawa Y
    Hinyokika Kiyo; 1992 Jul; 38(7):857-68. PubMed ID: 1381869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Terazosin in the treatment of benign prostatic hypertrophy].
    Andres M; De Cobelli O; Carmignani L; Musci R; Kocjancic E; Panizzutti M; Rocco F
    Arch Ital Urol Androl; 1995 Feb; 67(1):37-9. PubMed ID: 7538386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.
    Lepor H; Knapp-Maloney G; Wozniak-Petrofsky J
    Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):392-7. PubMed ID: 2477339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The use of terazosin hydrochloride (Hytrin) in the treatment of patients with benign prostatic hyperplasia].
    Sivkov AV; Apolikhin OI; Medvedev AA
    Urol Nefrol (Mosk); 1997; (5):50-3. PubMed ID: 9412019
    [No Abstract]   [Full Text] [Related]  

  • 8. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
    Elhilali MM; Ramsey EW; Barkin J; Casey RW; Boake RC; Beland G; Fradet Y; Trachtenberg J; Orovan WL; Schick E; Klotz LH
    Urology; 1996 Mar; 47(3):335-42. PubMed ID: 8633398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A randomized comparative study assessing once versus twice a day treatment of benign prostatic hyperplasia with terazosin].
    Suzuki H; Ohnishi T; Ikemoto I; Ohishi Y; Suzuki Y; Yamazaki H
    Hinyokika Kiyo; 2001 Feb; 47(2):77-81. PubMed ID: 11280890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH.
    Lepor H; Machi G
    Prostate; 1992; 20(2):89-95. PubMed ID: 1372430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
    Fourcade RO
    Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terazosin for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 1994 Feb; 36(916):15-6. PubMed ID: 7508075
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical experience: symptomatic management of BPH with terazosin.
    Dunzendorfer U
    Urology; 1988 Dec; 32(6 Suppl):27-31. PubMed ID: 2462302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of benign prostatic hyperplasia with alpha receptor blockers].
    Stockamp K
    Urologe A; 1995 Jan; 34(1):3-8. PubMed ID: 7533449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
    Pushkar' DIu; Kosko DV; Loran OB; Kan IaD; Sapozhnikov IM; Tevlin KP
    Urol Nefrol (Mosk); 1995; (4):32-5. PubMed ID: 7571199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of benign prostatic hyperplasia: terazosin or finasteride?].
    Trinkler FB
    Praxis (Bern 1994); 1997 Aug; 86(34):1305-6. PubMed ID: 9381019
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Patterns of use of terazosine in current medical practice in ambulatory patients with obstructive and irritative obstructive disorders of urination].
    Serment G; Rossi D; Reitz C; Boumendil O
    Prog Urol; 2000 Apr; 10(2):254-60. PubMed ID: 10857143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial.
    Johnson TM; Jones K; Williford WO; Kutner MH; Issa MM; Lepor H
    J Urol; 2003 Jul; 170(1):145-8. PubMed ID: 12796667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.